- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940127
AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks
AI-Driven Hip Exoskeleton Control Framework That Rapidly Generalizes to a Broad Range of Users and Real-World Locomotor Tasks
The goal of this clinical trial is to evaluate the feasibility of a prototype artificial intelligence (AI)-based controller for a lightweight hip exoskeleton across a broad range of users, including healthy younger adults (18-39 years) and older adults (65 years and older). The main questions it aims to answer are:
- Can the AI-based controller accurately estimate gait phase in real time across younger and older adults?
- How does hip exoskeleton assistance change walking energy cost, mechanics, and muscle activity?
Researchers will compare walking with powered hip exoskeleton assistance to walking without the exoskeleton and walking while wearing the exoskeleton with no assistance (zero torque).
Participants will:
- Complete a short screening and frailty assessment
- Walk on a treadmill under different conditions with and without the hip exoskeleton during 2 to 5 lab visits
- Wear motion capture markers, muscle activity (EMG) sensors, and a mask that measures breathing to estimate energy use
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study is funded by the National Institute of Biomedical Imaging and Bioengineering (R21EB037268) and conducted at the University of Texas at Austin in collaboration with Carnegie Mellon University. The CMU Hip Exoskeleton is a research prototype with powered hip joints for flexion and extension (peak torque 18 Nm, total weight 3.5 kg). Its controller uses joint angle and user-state estimates to command assistive torque, limited to less than 0.2 Nm/kg (at most about 30% of typical biological hip moments during walking), so it supplements rather than overrides the user's own muscle effort.
During each visit, participants walk on a force-instrumented treadmill at 1.25 m/s with safety harness and handrails. Researchers record whole-body motion capture, ground reaction forces, inertial measurement unit data, lower-limb electromyography, and metabolic energy expenditure via open-circuit indirect calorimetry. Walking conditions include no exoskeleton, exoskeleton worn with zero torque, and powered exoskeleton assistance. Outcomes will be compared across conditions and between younger and older adults using repeated-measures statistical analysis.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Owen Beck, PhD
- Telefoonnummer: 512-232-6025
- E-mail: owenbeck@austin.utexas.edu
Studie Locaties
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78712
- Werving
- University of Texas at Austin
-
Contact:
- Owen Beck, PhD
- Telefoonnummer: 512-232-6025
- E-mail: owenbeck@austin.utexas.edu
-
Contact:
- Dylan Page
- Telefoonnummer: 319-440-0869
- E-mail: dmp3799@my.utexas.edu
-
Hoofdonderzoeker:
- Owen Beck, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 to 39 years (younger adult group) or 65 years and older (older adult group)
- Willing and able to provide informed consent
- Able to walk independently without assistance
- No known cardiovascular, metabolic, or renal disease, and no signs or symptoms suggestive of such disease
- Cleared for light- to moderate-intensity exercise without the need for medical clearance under American College of Sports Medicine (ACSM) preparticipation screening guidelines
Exclusion Criteria:
- Age 40 to 64 years
- Leg surgery within the past 5 years
- Orthopedic disability that could impair movement or limit participation in the exercise protocol
- Neurologic disorder that may affect neuromuscular function or gait (e.g., stroke, Parkinson's disease, peripheral neuropathy, traumatic brain injury)
- Known metabolic or cardiovascular disease (hypertension alone is not exclusionary), or requiring medical clearance under ACSM guidelines without having obtained it
- Metal implants in the lower extremities, cardiac pacemaker, or other implanted electronic device
- Pregnancy
- History of seizure disorder or fainting (syncope)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Hip Exoskeleton Walking
Healthy younger adults (18-39 years) and older adults (65+ years) walk on an instrumented treadmill under multiple conditions across 2-5 lab visits: no exoskeleton, wearing the CMU Hip Exoskeleton with zero torque, and with powered assistance from the AI-driven hip exoskeleton controller (assistance limited to <0.2 Nm/kg). The primary objective is to evaluate real-time gait phase estimation accuracy of the prototype controller across users; metabolic cost, biomechanics, and muscle activity are recorded as secondary measures. |
A lightweight (3.5 kg) research hip exoskeleton developed at Carnegie Mellon University with powered hip flexion/extension joints, a backpack-mounted computer and battery, and thigh and waist interfaces secured with straps. An AI-driven controller estimates the user's gait state from joint angle and wearable sensor data and commands assistive hip torque in real time, limited to <0.2 Nm/kg (peak device torque 18 Nm). Participants walk on a treadmill with powered assistance, with the device worn at zero torque, and without the device. The device was determined by the UT Austin IRB to be a non-significant risk device.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gait Phase Estimation Error of the AI-Driven Hip Exoskeleton Controller
Tijdsspanne: Day 1
|
Root-mean-square error (RMSE) between the controller's real-time gait phase estimate and ground-truth gait phase derived from force-instrumented treadmill data during powered hip exoskeleton walking, reported as percent of the gait cycle (%). Used to evaluate feasibility of the prototype controller across younger and older adult users. |
Day 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Net Metabolic Power During Powered Hip Exoskeleton Walking
Tijdsspanne: Day 1
|
Net metabolic power (W/kg), measured by open-circuit indirect calorimetry with resting value subtracted, during treadmill walking at 1.25 m/s with powered hip exoskeleton assistance. |
Day 1
|
|
Peak Hip Joint Moment During Powered Hip Exoskeleton Walking
Tijdsspanne: Day 1
|
Peak biological hip extension moment (Nm/kg), computed from motion capture and force-instrumented treadmill data, during treadmill walking with powered hip exoskeleton assistance. |
Day 1
|
|
Lower-Limb Muscle Activity During Powered Hip Exoskeleton Walking
Tijdsspanne: Day 1
|
Average electromyography (EMG) amplitude normalized to maximum voluntary contraction (%MVC), averaged across eight recorded lower-limb muscles, during treadmill walking with powered hip exoskeleton assistance. |
Day 1
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Inseung Kang, PhD, Carnegie Mellon University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- STUDY2026_00000477
- R21EB037268 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data underlying published results will be shared, including biomechanics (motion capture, ground reaction forces), electromyography, metabolic, and exoskeleton sensor/controller data, along with participant characteristics (age group, sex, height, mass). Identifiable information, including video recordings, will not be shared.
IPD-tijdsbestek voor delen
Data will be made available no later than the time of associated publication or the end of the award period, whichever comes first, and will remain available for at least 5 years.
IPD-toegangscriteria voor delen
De-identified data and supporting information will be deposited in a public data repository and made openly available to researchers without restriction, subject to the repository's terms of use.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ANALYTIC_CODE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .